Arthneeti
Torrent Pharma.Q4 FY23

Torrent Pharma. Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹4,595P/E: 80.5Market Cap: ₹1.7L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Torrent Pharma. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Torrent Pharma. management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Torrent Pharma. — get its next earnings analysis in your feed

How does Torrent Pharma. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisTorrent Pharma.
See where Torrent Pharma. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Torrent Pharma. rank in Pharmaceuticals & Biotechnology?

Compare Torrent Pharma. against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Torrent Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Valiant Laborato (Q2 FY27)

    Year-on-Year Revenue Growth:** Approximately 152.8% increase (from Rs. Key results statement takeaways from Valiant Laboratories Ltd's Q2 FY27 results statement

  • Wockhardt Ltd (Q2 FY27)

    969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • JFL Life (Q2 FY27)

    This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea

  • P & G Health Ltd (Q2 FY27)

    Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Laurus Labs

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →